Program
TOLLB-001
A development code. Also written as “TollB-001 tablets”, “TollB-001” and “TollB-001 Tablet”.
Its studies are mostly in Arthritis, Rheumatoid · Scleroderma, Systemic, led by Toll Biotech Co. Ltd. (Beijing).
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Toll Biotech Co. Ltd. (Beijing) | 32 open or running | phase 2since Jan 29, 2026 | Sep 22, 2023 | Dec 2026phase 2 · NCT07408024 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 22, 2023First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT06103773 · 98 enrolled · China
- Jan 29, 2026Phase 2 study in Arthritis, RheumatoidPhase 2 reachedNCT07408024 · 24 planned · China
- Jul 28, 2026Phase 2 study in Scleroderma, SystemicNCT07745725 · 36 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Arthritis, RheumatoidNCT07408024
- Oct 2027Primary completion: phase 2 study in Scleroderma, SystemicNCT07745725
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07745725Scleroderma, Systemic · China | 2 | Not yet recruiting | Oct 2027 | 36 |
| NCT07408024Arthritis, Rheumatoid · China | 2 | Recruiting | Dec 2026 | 24 |
| NCT06103773Arthritis, Rheumatoid · China | 1 | Completed | Apr 7, 2025 | 98 |
How it is read
Names in the registry
- “TollB-001 tablets”, 1 entry
- “TollB-001”, 1 entry
- “TollB-001 Tablet”, 1 entry
Codes read as this program: TOLLB001.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 2 studies
- Scleroderma, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.